Healthcare Industry News: natalizumab
News Release - January 23, 2006
Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Multiple Sclerosis
CAMBRIDGE, Mass. and DUBLIN, Ireland--(HSMN NewsFeed)--Jan. 23, 2006--Biogen Idec (NASDAQ: BIIB ) and Elan Corporation, plc. (NYSE: ELN ) announced today that they have received notification from the U.S. Food and Drug Administration (FDA) that the Peripheral and Central Nervous System Drugs Advisory Committee will review TYSABRI® (natalizumab) for the treatment of multiple sclerosis (MS) on March 7, 2006.The sBLA includes two-year data from the Phase III AFFIRM monotherapy trial and SENTINEL add-on trial with AVONEX® (Interferon beta-1a) in MS, a revised label and risk management plan, and an integrated safety assessment of TYSABRI clinical trial patients. Biogen Idec and Elan also recently completed a comprehensive safety evaluation of more than 3,000 TYSABRI patients in collaboration with leading experts in progressive multifocal leukoencephalopathy (PML) and MS. The results yielded no new confirmed cases of PML beyond the three previously reported.
About Biogen Idec
Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.
Safe Harbor/Forward Looking Statements
This press release contains forward-looking statements regarding the potential and regulatory path forward of TYSABRI. The commercial potential and regulatory path forward of TYSABRI are subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the companies' current expectations include the risk that concerns may arise from additional data or analysis or that the companies may encounter other unexpected delays or hurdles. There is also no assurance that the companies will be able to resume marketing and sales of TYSABRI. Drug development and commercialization involves a high degree of risk. For more detailed information on the risks and uncertainties associated with the companies' drug development and other activities, see the periodic reports that Biogen Idec and Elan have filed with the Securities and Exchange Commission. The companies assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Biogen Idec
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
